Diabetic nephropathy (DN) is a major complication associated with both type 1 and type 2 diabetes, and a leading cause of end-stage renal disease. Conventional therapeutic strategies are not fully efficacious in the treatment of DN, suggesting an incomplete understanding of the gene regulation mechanisms involved in its pathogenesis. Furthermore, evidence from clinical trials has demonstrated a “metabolic memory” of prior exposure to hyperglycemia that continues to persist despite subsequent glycemic control. This remains a major challenge in the treatment of DN and other vascular complications. Epigenetic mechanisms such as DNA methylation, nucleosomal histone modifications, and noncoding RNAs control gene expression through regulation of chromatin structure and function and post-transcriptional mechanisms without altering the underlying DNA sequence. Emerging evidence indicates that multiple factors involved in the etiology of diabetes can alter epigenetic mechanisms and regulate the susceptibility to diabetes complications. Recent studies have demonstrated the involvement of histone lysine methylation in the regulation of key fibrotic and inflammatory genes related to diabetes complications including DN. Interestingly, histone lysine methylation persisted in vascular cells even after withdrawal from the diabetic milieu, demonstrating a potential role of epigenetic modifications in metabolic memory. Rapid advances in high-throughput technologies in the fields of genomics and epigenomics can lead to the identification of genome-wide alterations in key epigenetic modifications in vascular and renal cells in diabetes. Altogether, these findings can lead to the identification of potential predictive biomarkers and development of novel epigenetic therapies for diabetes and its associated complications.
glomerulosclerosis, tubular atrophy, and podocyte apoptosis/dysfunction. Clinically, DN is identified by albuminuria, rising creatinine levels, and aberrant glomerular filtration rates. Signal transduction mediated by key factors associated with diabetes, such as high glucose (HG), advanced glycation end products (AGEs), oxidized lipids, proinflammatory cytokines, and local growth factors including transforming growth factor-β1 (TGF-β1) and angiotensin II (Ang II), can lead to renal hypertrophy and fibrosis through various biochemical mechanisms [1–6].

Several treatment strategies are available to cure DN or reduce its progression. These include modalities used to suppress the renin–angiotensin–aldosterone system and control blood glucose levels. However, diabetic patients are still reaching ESRD at an alarming rate. Moreover, clinical and experimental studies have shown that the risk and severity of diabetic complications, including DN, seem to persist even after glucose normalization, suggesting a “metabolic memory” of the prior exposure to HG [7,8]. These findings imply that the current knowledge based on biochemical mechanisms, genetics, and proteomics research [6,9–12] does not explain the pathophysiology of DN completely. More than a decade after the human genome has been sequenced, it is becoming increasingly clear that changes in the DNA sequence and genetic mutations alone cannot fully explain the diversity of cellular responses and disease incidence in the general population. On the other hand, epigenetic mechanisms in chromatin can also regulate gene expression, cellular identity, phenotypic variations, and disease states without any alterations in the underlying DNA sequence. Epigenetics can be influenced profoundly by diet, lifestyle, and the environment—key factors associated with the etiology of diabetes [13,14]. Thus, complex interactions between genes and the environment can play significant roles in common human diseases such as diabetes and related pathologies. Given the high incidence and debilitating nature of DN, it is imperative to evaluate additional mediatory factors and therapeutic targets. The current review focuses on epigenetics and the emerging evidence for epigenetic mechanisms in diabetes and its complications, with special emphasis on DN.

Epigenetics

The term “epigenetics” originally referred to the programmed changes during development that cannot be explained by conventional genetics [15]. Epigenetics typically refers to changes in gene expression and phenotype, including those conferred mitotically or meiotically, that occur without any alterations in the underlying DNA sequence. More recently, epigenetics is defined as “the structural adaptation of chromosomal regions so as to register, signal, or perpetuate altered activity states” to account for alterations in the chromatin state [15,16]. Epigenetic signals regulate gene expression through chromatin remodeling, which in turn regulates chromatin structure and access to transcription factors and coregulators. Epigenetic control of gene regulation plays an important role in embryogenesis, cellular differentiation and development, cell identity, genomic imprinting, immune cell function, stem cell plasticity, transcriptional memory, and cellular responses to environmental signals [17–19]. Poor dietary choices and exposure to environmental pollutants can regulate epigenetic mechanisms to induce abnormal metabolic phenotypes that can be further compounded by genetic susceptibility [14,20]. Furthermore, environmentally induced epigenetic modifications could lead to phenotypic changes that persist even long after the original exposure was removed. Several studies also demonstrated the transgenerational inheritance of epigenetic changes, thus highlighting the potential effect of maternal malnutrition or overnutrition on the fetus that can result in deleterious effects later in adult life, including predisposition to diabetes and associated complications [13,21,22]. However, whether low birth weight increases the risk for DN is still not clear [23]. Furthermore, while the role of genetic factors associated with DN has been examined extensively, the role of epigenetics is only recently being considered.

Epigenetic modifications in chromatin and the epigenome

Chromatin, the site of epigenetic modifications in the nucleus, is composed of chromosomal DNA tightly packaged into repeating units called nucleosomes. Each nucleosome is made up of 146 bp DNA, which is wrapped around an octamer protein complex consisting of dimers of core histone proteins H2A, H2B, H3, and H4 held together by a linker histone H1 [24]. Chromatin structure is dynamically regulated by epigenetic modifications between transcriptionally silent “heterochromatin” and active “euchromatin” states (Fig. 1). These include covalent post-translational modifications (PTMs) of nucleosomal histones as well as DNA methylation (DNAMe), while noncoding RNAs such as micro-RNAs can also regulate gene expression by post-transcriptional epigenetic mechanisms. Epigenetic modifications provide docking sites for proteins/enzymes that alter chromatin structure, remodel nucleosomes, and erase or recruit other transcription regulators. Combinatorial effects of epigenetic modifications on promoters, enhancers, and other regulatory elements of the genome dictate gene expression patterns and the resultant phenotypes under normal and pathophysiological conditions [20,21,25]. Genome-wide patterns of these modifications collectively form the “epigenome,” which is cell-type specific, can be modulated by environmental cues, and can lead to aberrant gene expression associated with human diseases [13,20,26].

DNAMe, the most highly studied epigenetic modification, generally takes place on cytosines of CpG dinucleotides in regions known as “CpG” islands located in chromosomal DNA. DNAMe is catalyzed by DNA methyltransferases (DNMTs) that transfer methyl group from S-adenosyl-methionine to the 5’ position of cytosine (5’-methyl cytosine). In mammalian cells, DNMT3A and DNMT3B mediate de novo methylation while DNMT1 acts as a maintenance methyl transferase [18]. Promoter DNAMe generally leads to gene silencing via multiple mechanisms including inhibition of transcription factor binding, increasing nucleosome occupancy at transcriptional start sites, regulation of histone PTMs and chromatin remodeling, cross-talk with histone methyltransferases, acetylases and deacetylases, and recruitment of methyl binding proteins such as MeCP2 [18,27]. Similar to other epigenetic modifications, DNAMe is now also known to be reversible [28,29]. Non-CpG methylation has also been found in pluripotent cells such as embryonic stem cells or early embryos [30,31], but it is not common in adult somatic tissues [32]. Although the role of non-CpG island methylation in mammals is largely unknown, recent studies have shown that it may also promote gene silencing and contribute to tumorigenesis [33]. DNAMe regulates important biological processes such as imprinting,
sphate (ADP)-ribosylation, and ubiquitination (Table 1) [17,25].

Histone PTMs include lysine acetylation (KAc), lysine methylation (KMe), arginine methylation, serine/threonine phosphorylation, SUMOylation, and non-coding RNAs including microRNAs also regulate chromatin structure and function (not shown). Genome-wide patterns of DNAMe and histone modifications are referred to as the “epigenome.” Its response to internal and external signals regulates gene expression involved in diverse biological processes and disease conditions. DNAMe, DNA methylomes; KAc, lysine acetylation.

differentiation, and X chromosome inactivation. It has been studied extensively because gene silencing of tumor suppressors and cell-cycle regulators via promoter hypermethylation has been associated with several cancers. Key epigenetic enzymes and cell-cycle regulators via promoter hypermethylation have been renamed as lysine acetyltransferases, lysine methyltransferases (HMTs) mediate KMe and are erased by histone deacetylases (HDACs). On the other hand, histone lysine demethylases (HDMs). Recently, these enzymes have been renamed as lysine acetyltransferases, lysine methyltransferases, and lysine demethylases, because they can also modify lysines in nonhistone proteins [37].

Histone modifications such as H3K9/14 or H4K12/16 acetylation at gene promoters and enhancers are generally epigenetic marks for active gene transcription. HKAc is mediated by HATs such as CBP/p300 and SRC-1, which also act as coactivators. Acetylation of lysine residues in histone tails neutralizes the positive charge and destabilizes interactions between histones and DNA as well as nucleosome–nucleosome interactions. In addition, the acetylated residues act as docking sites for chromatin remodeling proteins, leading to chromatin relaxation and increased accessibility to the transcription machinery. HATs are quite nonselective and acetylate several lysine residues in both histone and non-histone proteins [17,38]. However, profiling approaches such as chromatin immunoprecipitation followed by next-generation DNA sequencing (ChIP-Seq) revealed differences in the genome-wide distribution of individual HATs [39]. Genome-wide approaches also showed that enhancers are usually associated with CBP and p300 along with histone lysine monomethylation (H3K4me1) [40–42].

HDACs remove HKAc marks and mediate gene repression. They are subdivided into four classes, I–IV, depending on their structure, function, and mode of action. HDACs restore the positive charge of histone lysines and promote chromatin condensation, resulting in decreased chromatin access and reduced rates of transcription. HDACs have multiple functions, which can be attributed to their low substrate specificity. Their actions can be regulated at the level of both gene expression and promoter-specific recruitment [43]. Studies in knockout mice revealed specific functions of HDACs in vivo, including embryonic stem cell differentiation and cardiovascular effects [44–46]. The function of HDAC in cancer cells has been studied extensively, and several HDAC regulators are being used to treat cancers [35,47].

HKme is very interesting since it can be associated with either active or repressed genes depending on the modified lysine residue (Table 1). Furthermore, lysine residues can be mono (me1), di (me2), or tri (me3) methylated, adding another level of complexity. H3K4me1, H3K36me, and H3K79me are usually associated with active promoters and gene bodies, while H3K9me, H3K27me, and H4K20me promote transcription repression. In contrast, demethylation of H3K4me can inhibit transcription, whereas demethylation of H3K9me, H3K27me, and H4K20me marks can increase transcription. HDACs generally contain a SET domain that catalyzes methyltransferase activity, whereas demethylation activity in HDMs is mediated by amine oxidase-like domains or JmjC domains [25,48]. HMTs and HDMs are highly specific to the lysine residue being modified and also to the extent of methylation, e.g., SUV39H1 can mediate H3K9me3 but not H3K9me1, Ezh2 mediates H3K27me3, and SET7/9 mediates H3K4me1/me2. On the other hand, lysine-specific demethylase 1 (LSD1), the first HDAC regulator to be identified, can erase H3K4me1/me2, while the JARID1 family of demethylases removes H3K4me3. JmjId2a can erase both H3K9me3 and H3K36me3, while JmjId3 is specific to H3K27me3 [17,49] (Table 1). Recent high-throughput profiling of various histone PTMs associated with promoters, enhancers, and insulators led to the identification of such key regulatory elements genome wide [25,42,50,51]. Transcription start sites and promoters are enriched with H3K4me3 and H3K9/14Ac, enhancers with H3K4me1, and gene bodies of actively transcribed genes with H3K36me3. Histone modifications at enhancers also confer tissue- and cell-specific transcription in conjunction with lineage- or cell-specific transcription factors [25,42,52,53]. Histone modifications can also cross-talk with each other to regulate gene expression. Thus, H3K27me3 and
H3K4me3 can antagonize each other, and promoters with these bivalent modifications play important roles in stem cell differentiation [54]. H3K9Ac and Ser10 phosphorylation generally inhibit H3K9me to promote gene expression [17]. Cross-talk between histone PTMs and DNAMe has also been documented. DNAMe acts in concert with repressive histone modifications such as H3K9me3 to recruit transcription repressors and silence gene expression [20,55].

Regulation of histone-modifying enzymes plays a critical role in gene expression involved in key biological processes including differentiation, cancer, and diabetes and its complications [7,8,20,34,36,56,57]. In general, HKme is relatively more stable compared with other histone modifications. Therefore, similar to DNAme, H3Kme might be involved in the inheritance of epigenetic signatures to confer transcriptional memory that lasts long even after the removal of physiological or pathological signals. Polycomb repressive complex (PRC) proteins, which mediate the repressive H3K27me3 mark, remained tightly bound to chromatin during DNA replication, indicating a potential epigenetic role for such histone marks in the maintenance of transcription memory or epigenetic transmission [58,59]. Thus, alterations in HKme may contribute to the metabolic memory of transcription and persistent expression of pathologic genes implicated in diabetic complications [8,57]. As discussed earlier, epigenetic marks altered by the environment can be inherited during both somatic and germ cell replications [60]. Evidence shows that DNAme plays an important role in transgenerationally inherited obesity [61]. In addition, high-fat diets have been found to promote transgenerational transmission of adult-onset metabolic diseases in mice, suggesting an underlying epigenetic mechanism [62]. In epigenetic transmission, the role of DNAme is more apparent than that of histone modifications, although evidence also exists for the latter via PRCs and histone recycling [59,63].

In general, compared to genetic transmission, epigenetic transmission is more complex and needs further investigation, especially in the field of diabetes and its complications.

### Metabolic memory and diabetes complications

Hyperglycemia has been implicated in the development of numerous diabetic complications including nephropathy. Patients with both type 1 diabetes (T1D) and type 2 diabetes (T2D) continue to be at higher risk for developing complications even several years after achieving normoglycemia. This phenomenon of “metabolic memory” was clearly demonstrated in clinical trials such as the Diabetes Control and Complications Trial (DCCT) and the follow-up Epidemiology of Diabetic Interventions and Complications (EDIC) study [7,8,64]. The DCCT showed that intensive insulin therapy to attain strict glycemic control in T1D patients led to much better control of various vascular complications than conventional therapy [65]. Subsequently, both standard and intensive treatment DCCT groups were placed on intensive insulin therapy and followed up long term in EDIC study. Interestingly, EDIC study showed that those previously assigned to standard/conventional therapy in DCCT continued to develop complications, such as nephropathy and retinopathy, at significantly higher rates than the previous intensive therapy group in DCCT [66]. Recent reports demonstrate continued protection and lower rates of cardiac, renal, and retinal complications; lower blood pressure; more favorable lipid profiles; and reduced long-term risk for impaired glomerular filtration rate (GFR) in the former DCCT intensive therapy group [67–70]. Other clinical trials in T2D patients also demonstrated that a similar memory phenomenon, termed “legacy effect,” in those with lower fasting blood glucose and strict glycemic control resulted in lower rates of vascular complications [71–73]. These studies clearly

---

**Table 1. Histone modifications and their function in the transcription regulation**

| Modification | Histone | Modifying enzyme | Proposed function |
|--------------|---------|------------------|-------------------|
| Acetylation  | H2A, H3, H4 | ATF2, ELP3, GCN5, GTF3C4, HAT1, MORF, MOZ, p300, PCAF, SRC-1, TAF1, Tip 60 | Activation |
| Deacetylation| H2A, H3, H4 | HDAc1–HDAc11, SIRT1–SIRT7 | Repression |
| Methylation  | H1K26, H3K27 | Ezh2 | Repression |
|              | H3K9     | ESET, G9a, SUV39H1, SUV39H2, SETDB1 | Repression |
|              | H3K4     | MLL, SET7, SET9, SMYD3 | Activation |
|              | H3K36    | SETD2, NSD1 | Activation |
|              | H3K9    | DOT1L | Activation |
|              | H4K20    | PR-SET7, SUV4-20H1, SUV4-20H2 | Repression |
|              | H3R17    | CARM1 | Activation |
|              | H4R3     | PRMT1 | Activation |
|              | H3R8     | PRMT5 | Repression |
|              | H4R3     | PRMT5 | Repression |
| Demethylation| H3K4    | LSD1 | Repression |
|              | H3K4    | JARID1A, JARID1B, JARID1C, JARID1D | Repression |
|              | H3K9    | JMJD1A | Activation |
|              | H3K9/H3K36 | JMJD2A, JMJD2B, JMJD2C, JMJD2D | Activation/Repression |
|              | H3K36    | JHDM1A, JHDM1B | Activation |
|              | H3K27    | JMJD3, UTX | Activation |
| Phosphorylation| H2A51, H3S10, H3S28 | MSK1 | Repression |
|              | H3S10   | Aurora-B, IKK-α, MSK2, RSK2 | Activation |
| Ubiquitylation| H2AK119 | ATR, ATM, DNA-PK, CK2, Tel1 | DNA repair |
|              | H2BK120 | RING1B | Activation/repression |
| Biotinylation | H2AK9, H2AK13, H3K4, H3K9, H3K18, H4K12 | Biotinidase | Activation |

* References [17,20,36].
demonstrated the benefits of strict glycemic control and the fact that a memory of prior exposure to hyperglycemia might play a significant role in the subsequent risk of diabetic complications including nephropathy. However, mechanisms of metabolic memory are not clear and remain a major obstacle in the prevention or treatment of diabetic complications. As discussed later, recent studies have evaluated a role for epigenetic mechanisms in metabolic memory.

Several experimental cell culture and animal models have been developed to understand the mechanisms involved in metabolic memory. Endothelial cells (ECs) cultured in HG for short time periods continued to exhibit enhanced oxidative stress, and profibrotic and inflammatory genes even after return to normal glucose [74–76]. Vascular smooth muscle cells (VSMC) derived from the aortas of T2D db/db mice exhibited enhanced proinflammatory responses even after culturing ex vivo for a few weeks [77,78]. In T1D dogs, islet transplantation performed 12 weeks after the development of diabetes did not prevent progression to retinopathy, compared to that after 6 weeks [79]. Similarly, in T1D rats, reinstatement of glycemic control following several weeks of poor glycemic control did not reverse inflammation or progression to retinopathy and nephropathy [80–83]. Thus, both clinical and experimental evidences suggest that prior exposure to hyperglycemia can have long-lasting deleterious effects even after subsequent glycemic control. Other related factors associated with hyperglycemia and diabetes such as AGEs may also contribute to metabolic memory, because AGEs can modify various cellular proteins and enzymes to cause long-lasting changes in their functions, or can activate multiple signaling pathways via the receptor for AGE (RAGE) to induce inflammatory genes [84,85]. Furthermore, dyslipidemia and insulin resistance associated with T2D may also be involved. It is likely that these factors acting independently or cumulatively can lead to changes in epigenetic histone PTMs and DNAMe in target cells, thus contributing to metabolic memory (Fig. 2).

**DNAMe and diabetes complications**

DNAMe is the most stable and heritable epigenetic modification and is known to play an important role in normal as well as pathophysiological processes. However, its involvement in diabetes and its complications is less well studied. Early studies with mouse models showed that regulation of the Agouti gene by DNAMe plays a key role in the development of coat color, diabetes, and obesity. Interestingly, these studies also demonstrated the influence of external factors such as maternal diet on epigenetic processes and the transgenerational inheritance of DNAMe [60,86]. In a model of intrauterine growth retardation (IUGR) in rats, it was found that the development of diabetes was associated with promoter hyper-DNAMe and inhibition of the islet-specific transcription factor Pdx1 that regulates insulin gene expression in pancreatic β cells. DNAMe was also found to be related to downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) and IGF1r in pancreatic islets and skeletal muscles of T2D animals and patients [87–89]. PGC-1α downregulation led to the inhibition of insulin expression and mitochondrial biogenesis [87,88]. Furthermore, in another study, insulin promoter DNAMe in islets of T2D patients was correlated with lower insulin levels and elevated HbA1c levels [90]. Another recent study on monozygotic twins reported a 10% increase in global DNAMe at Alu repetitive elements in peripheral blood leukocytes, which showed significant correlation with insulin resistance [91]. Genetic association studies have identified single nucleotide polymorphisms in the fat mass and obesity-associated (FTO) gene region with a risk of adiposity. Functional studies showed that FTO controls feeding behavior and energy expenditure [92]. Interestingly, recent studies in T2D patients showed a small but significant decrease in DNAMe at a CpG site in the first intron of the FTO gene [93]. Furthermore, this hypomethylation was also observed in healthy individuals who later progressed to impaired glucose metabolism. These unique findings suggest a correlation between epigenetic DNAMe variations and predisposition to T2D [93].

Studies, reported to date, investigating kidneys of diabetic animal models or renal cells treated in vitro with HG have not demonstrated significant changes in DNAMe [94–96]. On the other hand, whole blood genomic DNA from T1D patients with DN exhibited differential DNAMe patterns at 19 genes including UNC13B, relative to those without nephropathy [97]. Interestingly, UNC13B was correlated with DN in genetic studies, suggesting an association between DNAMe and DN susceptibility. Several differentially methylated genes were
also identified in DNA extracted from saliva of ESRD patients compared to patients with chronic kidney disease who did not progress to ESRD [98]. However, relevance of these findings to DN awaits further investigation. It is likely that high-throughput approaches using genomic DNA and target tissue biopsies from various clinical cohorts or animal models will clarify the relationship between DNAm and diabetic complications including nephropathy. In this connection, it is noteworthy that a recent genome-wide profiling study using next-generation sequencing demonstrated significant changes in DNAm in HG-treated ECs at several genes related to diabetes and its complications. Reciprocal relations with histone acetylation were also demonstrated [99].

**Histone modifications, diabetes complications, and metabolic memory**

Progress in the study of histone PTMs has grown by leaps and bounds in the field of cancer. However, it is still in its infancy in the field of diabetes. Recent studies have shed some insights into the role of histone modifications in diabetes, diabetic complications, and metabolic memory. Histone PTMs have been implicated in the regulation of insulin expression by Pdx1 in pancreas. In response to elevated glucose levels, Pdx1 could recruit the HAT coactivator p300 and HMT SET7 to the insulin promoter, which could promote chromatin relaxation by increasing H3K9/14Ac and H3K4me1/2, respectively, to enhance insulin transcription. In contrast, Pdx1 could recruit HDACs to inhibit insulin expression when glucose levels were low [100–102]. Interestingly, it was found that IUGR reduces insulin gene expression by inhibiting Pdx1 expression via alterations in promoter H3KAc, H3K4me3, and DNAm in the offspring [103]. H3K9me2 and H3K4me2, as well as the related enzymes SETDB1 (H3K9 methyl transferase) and LSD1 (H3K4 demethylase), were reported to play critical roles in adipocyte differentiation [104]. More direct evidence for histone modifications in diabetes was suggested in a report, which showed that mice deficient in Jhdm2a, an H3K9me2 demethylase, appear to play important regulatory roles in these events [105]. A recent genome-wide analysis of histone modifications revealed a global snapshot of the islet chromatin, and several islet-specific enhancers were identified. Interestingly, many of them were located in genetic loci previously associated with T2D [106]. HDACs were also shown to regulate the acetylation of several transcription factors involved in adipocyte differentiation, suggesting an important role for non-HKAc in metabolic disorders [107,108]. However, the role of HDACs in epigenetic mechanisms involved in diabetes complications and the potential use of HDAC inhibitors are not well studied.

Aberrant promoter histone modifications can be triggered by HG and other diabetogenic agents to affect adversely the expression of key target genes associated with complications. Several studies have examined the role of histone PTMs in the regulation of inflammatory gene expression in ECs, monocytes, VSMCs, and renal mesangial cells (MCs), all of which are key cell types involved in diabetes complications [6,57,109–112]. Endothelial dysfunction, increased oxidant stress, and reduced nitric oxide are major features of diabetic micro- and macrovascular complications. In particular, this is associated with decreased levels or activity of the endothelial nitric oxide (eNOS) enzyme and is exemplified in studies involving eNOS knockout mice [109]. Diabetes reduces NO bioavailability, resulting in increased EC proliferation, inflammatory gene expression, VSMC activation, and macrophage infiltration, which are the key factors in the development of DN [109,110]. EC-specific expression of eNOS involves formation of an open chromatin near the eNOS promoter marked by increased H3/H4KAc and H4Kme [113,114]. Interestingly, hypoxia, a known mediator of EC dysfunction and a potential risk factor for DN [115], also inhibits eNOS expression through reversal of these promoter-specific histone modifications [116]. Other studies have shown that gene expression in monocytes and macrophages is also regulated by histone modifications, which play key roles in inflammation and macrophage polarization [57,117]. JMJD3, an H3K27me3 demethylase, and HDAC11 appear to play important regulatory roles in these events [118–120]. HG-induced inflammatory gene expression was associated with increased promoter H3/H4KAc, and enhanced recruitment of HATs CBP/P300 as well as the proinflammatory transcription factor NF-kB in THP-1 monocytes. Furthermore, monocytes from diabetic patients exhibited enhanced H3KAc at the promoters of key inflammatory genes, confirming in vivo relevance [121]. SET7, an H3K4 methyltransferase, was implicated in NF-kB-mediated inflammatory gene expression in TNF-α-treated THP-1 monocytes, and in macrophages from diabetic mice [122]. Profiling studies using ChIP linked to microarrays (ChIP-on-chip) revealed key differences in the patterns of repression (H3K9me2) and activation (H3K4me2) histone modifications at coding regions of HGregulated genes in THP-1 monocytes, with in vivo relevance being shown in primary monocytes from diabetes patients [123]. Furthermore, comparative ChIP-on-chip epigenome profiling of lymphocytes from T1D patients with those from normal control volunteers revealed significant alterations in H3K9me2 at a subset of genes related to T1D and closely associated with autoimmune functions and inflammation [124], further demonstrating the role of histone modifications in diabetes and its complications. Recent ChIP-on-chip studies with chromosome 6 tiling arrays in monocytes of T1D patients versus normal control individuals revealed key variations in H3K9Ac at the upstream enhancer regions of two HLA genes whose single nucleotide polymorphisms (SNPs) are known to be closely related with T1D [125], suggesting potential connections between genetic SNPs and surrounding epigenetic marks in the etiology of diabetes.

Emerging evidence supports a role for histone modifications in the regulation of key gene complexes associated with DN. In a rat model of T2D-induced DN, hyperglycemia in the kidneys was associated with reduced levels of active chromatin marks H3KAc and Ser10 phosphorylation at the fibrillin 1 and collagen type III alpha1 gene promoters [126]. Changes in global histone modifications were seen in the kidneys of uninephrectomized diabetic db/db mice [127]. Furthermore, HDAC2 activity was increased in kidneys of diabetic animals, and inhibition of HDAC activity blocked diabetic-induced fibrotic gene expression [128]. Recently, evidence of epigenetic mechanisms in HG- and TGF-β1-induced fibrotic gene expression in renal MCs was demonstrated for the first time [129]. In these studies, the induction of key profibrotic genes by HG and its downstream effectors TGF-β1 was associated with decreases in activation marks (H3K4me1, H3K4me2, and H3K4me3) and increases in repressive marks (H3K9me-1 and H3K9me-2) at these gene promoters. Furthermore, HG and TGF-β1 could induce the expression of SET7, while SET7 gene silencing inhibited TGF-β1-induced expression of fibrotic genes. Interestingly, pretreatment with TGF-β1 antibodies
significantly inhibited HG-induced profibrotic gene expression and alterations in histone modifications at their promoters [129]. These results demonstrate the involvement of histone PTMs in HG- and TGF-β1-induced genes relevant to DN (Fig. 3).

Role of histone modifications was also demonstrated in some nondiabetic kidney diseases. Thus, reports showed that aldosterone can reverse Dot1a-mediated promoter repressive H3K9me mark to increase the expression of the epithelial Na (+) channel alpha (ENaC) gene in the renal collecting ducts [130,131]. In other studies, increased expression of inflammatory genes such as MCP-1 in a model of renal ischemic injury was associated with increased H3K4me3 and recruitment of the chromatin remodeling enzyme Brahma-related gene-1 (BRG1) at these gene promoters [132]. Changes in repressive histone PTMs were associated with collagen III gene expression in aging-induced nephropathy [133]. Notably, epigenetic mechanisms have been implicated in renal development and maintenance of podocyte-differentiated function [134,135]. Together, these data demonstrate that histone PTMs are involved in the regulation of genes associated with chronic as well as acute renal injuries, and even with renal development. However, such candidate-gene-based approaches can only provide a glimpse of a complex epigenetic landscape. Genome-wide high-throughput profiling approaches can help provide valuable information about the state of the epigenome in DN.

Recent studies using cell and animal models have suggested that histone modifications might be associated with metabolic memory. In one study, there was enhanced histone gene expression in VSMCs cultured from T2D db/db mice for several passages relative to those from genetic control db/+ mice, and this was associated with persistently reduced H3K9me3 and occupancy of corresponding methyl transferase Suv39h1 at inflammatory gene promoters [78]. Furthermore, there was also reduced levels of Suv39h1 in the diabetic db/db VSMCs, which was found to be due to an increased expression of the microRNAs miR-125b that targets Suv39h1 [136]. The miR-125b mimics could reduce Suv39h1 levels, upregulate inflammatory genes in nondiabetic cells, and also promote monocyte binding in db/+ VSMCs to induce a diabetic phenotype. This demonstrates a novel-cross-talk between microRNAs and epigenetic mechanisms in diabetic vascular inflammation and metabolic memory. In another model of metabolic memory, short-term exposure of ECs to HG led to persistently increased expression of p65 (active subunit of NF-kB) and inflammatory genes for several days even after returning to normal glucose. This was associated with higher promoter levels of H3K4me1 and occupancy of the corresponding SET7 H3K4 methyl transferase [76,137]. A key role for oxidant stress in promoting metabolic memory in ECs was suggested in this and other studies [74,76,89]. Interestingly, in a rat model of diabetic retinopathy and metabolic memory, retinal ECs exhibited reduced expression of sod gene that codes for the protective antioxidant protein superoxide dismutase. This was associated with increased levels of the repressive mark H4K20me3 and occupancy of the corresponding methyltransferase Suv420h at the sod gene promoter, leading to repression of superoxide dismutase [83]. Together, these studies support a key role for histone modifications in metabolic memory of diabetic vascular complications that seem to persist despite glycemic control (Fig. 2). Since renal MCs, tubular epithelial cells, ECs, and podocytes are also affected by HG and diabetes, similar mechanisms in these cells in vivo might also contribute to metabolic memory of DN. Moreover, it has recently been speculated that epigenetic mechanisms may also regulate hypertension, which is associated with both diabetic and nondiabetic renal diseases and can persist across generations [138].

Resources and technologies for epigenomics research in diabetes and its complications

The National Institutes of Health Roadmap Epigenomics Program is focused on mapping the locations and characterizing the functions of epigenetic modifications in normal and diseased states using numerous cell types and tissues. These epigenomic maps are being made available to the entire scientific community (http://www.ncbi.nlm.nih.gov/epigenomics) and will be a tremendous resource for future research. Recent advances in next-generation sequencing and related technologies as well as in bioinformatics tools have accelerated epigenomics research significantly [25,139,140]. These include ChIP-on-chip and ChIP-Seq to study genome-wide patterns of histone modifications [25,57,139,141]. DNAme is traditionally studied using bisulfite conversion of 5′-methyl cytosine or approaches to enrich methylated DNA [142,143]. These are coupled to microarrays or next-generation DNA-Seq analysis to determine genome-wide distribution of DNAme [57,144]. Novel features of the epigenome, including key regulatory elements/regions, have been uncovered from the combinatorial and integrative analyses of genome-wide patterns of histone PTMs and DNAme along with transcriptome analyses of gene expression patterns [25,42,50,51,140,145]. These technologies are gradually being utilized to decipher the epigenomes of key target cells involved in diabetes and its complications. Utilization of these genome-wide profiling technologies to study renal biopsies or genomic DNA from patients with DN or other renal diseases relative to
normal control individuals can yield significant information regarding the epigenome of normal versus diseased kidneys, which in turn could open the doors for the development of novel therapeutic opportunities. However, it is also important to consider conducting such studies on cells or tissues that manifest the disease, since the epigenome is cell-type specific. This could pose a challenge in renal research due to the multacellular nature of the kidney.

Summary

Increasing evidence supports the critical role of hyperglycemia and downstream mediators such as AGEs, Ang II, and TGF-β in signaling, molecular, and chromatin-based mechanisms in the development of metabolic memory and diabetic complications (Fig. 2). However, diabetes leads to multiorgan dysfunction and is associated with several physiological abnormalities, including insulin resistance and dyslipidemia (T2D) and autoimmune disorders (T1D). It is further complicated by dietary choices and the lifestyles. Although numerous studies have examined the role of genetic variants in the pathology of diabetes complications such as DN, very few candidate loci with functional associations have been uncovered. Given the strong influence of environmental factors, the additional role of epigenetics is worth considering. Furthermore, metabolic memory still remains a major obstacle in the treatment and prevention of diabetes complications. Recent advances in high-throughput genomic sequencing approaches should make it feasible to better understand the epigenome state in diabetes and related complications such as DN. Important, they might reveal key differences in the epigenome between patients who progress to DN and other complications and those who do not. Unlike genetic changes, epigenetic changes are reversible, which thus provides a window of opportunity for therapeutic development. Several epigenetic regulators such as inhibitors of DNAmE, HDACs, HATs, and DNMTs are already being used for cancer treatment, and some are being evaluated for vascular disorders such as restenosis [35,47,146,147]. Recent studies showing reversal of epigenetic modifications associated with islets [103], ECs [113], monocytes [148], and renal cells [128,129,149] indicate that epigenetic therapy for diabetic complications is a distinct possibility. Further work in this rapidly expanding area of research could advance our knowledge of epigenetic mechanisms involved in the pathogenesis of DN and other diabetic complications, which in turn could lead to new therapeutic strategies.

Conflict of interest

None declared.

Acknowledgments

The authors gratefully acknowledge funding from the National Institutes of Health (NIDDK and NHLBI), the Juvenile Diabetes Research Foundation, and the American Diabetes Association.

References

[1] Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator. J Am Soc Nephrol;15(Suppl 1): S55–S57, 2004
[2] Declives AE, Sharma K: New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6:371–380, 2010
[3] Ramsamy R, Yan SF, Schmidt AM: Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243:88–102, 2011
[4] Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625, 2005
[5] Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77:S59–S59, 2000
[6] Brosius 3rd FC: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disorder 9:245–254, 2008
[7] Villeneuve LM, Natarajan R: The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 299:F14–F25, 2010
[8] Pirola I, Balerczuk A, Okabe J, El-Osta A: Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6: 665–675, 2010
[9] Susztak K, Böttinger EP: Diabetic nephropathy: a frontier for personalized medicine. J Am Soc Nephrol 17:361–367, 2006
[10] Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K: Transcriptome analysis of human diabetic kidney disease. Diabetes 60:2354–2369, 2011
[11] Thomas MC, Groop PH, Tryggvason K: Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens 21:195–202, 2012
[12] Rincon-Choles H, Thameem F, Lehman DM, Arya R, Nar N, Duggirala R, Stern MP, Abboud HE: Genetic basis of diabetic nephropathy. Am J Ther 12:555–561, 2005
[13] Jirtle RL, Skinner MK: Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253–262, 2007
[14] Ling C, Groop L: Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58:2718–2725, 2009
[15] Goldberg AD, Allis CD, Bernstein E: Epigenetics: a landscape takes shape. Cell 128:635–638, 2007
[16] Bonasio R, Tu S, Reinberg D: Molecular signals of epigenetic states. Science 330:612–616, 2010
[17] Kouzarides T: Chromatin modifications and their function. Cell 128:693–705, 2007
[18] Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J Cell Physiol 213:384–390, 2007
[19] Natoli G: Maintaining cell identity through global control of genomic organization. Immunity 33:12–24, 2010
[20] Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol 28:1057–1068, 2010
[21] Feil R, Fraga MF: Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 13:97–109, 2011
[22] Woroniecki R, Gaikwad AB, Susztak K: Fetal environment, epigenetics, and pediatric renal disease. Pediatr Nephrol 26:705–711, 2011
[23] Fagerudd J, Forsblom C, Pettersson-Fernholm K, Saraheimo M, Wadén J, Rönback M, Rosengård-Bärlund M, Björkestedt CG, Thorn L, Wessman M, Groop PH: Low birth weight does not increase the risk of nephropathy in Finnish type 1 diabetic patients. Nephrol Dial Transplant 21:2159–2165, 2006
[24] Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260, 1997
[25] Zhou VW, Goren A, Bernstein BE: Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:7–18, 2011
Dovey OM, Meissner A, Lander ES: The mammalian epigenome. Cell 128:669–681, 2007

Sanjosé-Oj, Maddison K, Clarke AR: Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 4:305–315, 2007

Wu SC, Zhang Y: Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11:607–620, 2010

Chen ZX, Riggs AD: DNA methylation and demethylation in mammals. J Biol Chem 286:18347–18353, 2011

Haines TR, Rodenhisier DJ, Ainsworth P: Allele-specific non-CpG methylation of the NF1 gene during early mouse development. Dev Biol 240:585–598, 2001

Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaensch R: Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 97:5237–5242, 2000

Law JA, Jacobsen SE: Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet 11:204–220, 2010

Han H, Cortez CC, Yang X, Nichols PW, Jones PA. Liang G: DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 20:4299–4310, 2011

Jones PA, Baylin SB: The epigenomics of cancer. Cell 128: 683–692, 2007

Kelly TK, De Carvalho DD, Jones PA: Epigenetic modifications as therapeutic targets. Nat Biotechnol 28:1069–1078, 2010

Bhaumik SR, Smith E, Shilatifard A: Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14:1008–1016, 2007

Allis CD, Berger SL, Cote J, Dent S, Jenuwein T, Kouzarides T, Marko M, Ruthenburg A, Workman J, Zhang Y: New nomenclature for chromatin-modifying enzymes. Cell 131:633–636, 2007

Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem 70:81–120, 2001

Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, Flores TC, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Tirabosco R, Natarajan R: PU.1 and C/EBPα synergistically program distinct response to NF-κB activation through establishing monococyte specific enhancers. Proc Natl Acad Sci U S A 108:5290–5295, 2011

Taberlay PC, Kelly TK, Liu CC, You JS, de Carvalho DD, Miranda TB, Zhou XJ, Liang G, Jones PA: Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell 147: 1283–1294, 2011

Herz HM, Nakanishi S, Shilatifard A: The curious case of bivalent marks. Dev Cell 17:301–303, 2009

Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10: 295–304, 2009

Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 107:1058–1070, 2010

Reddy MA, Natarajan R: Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 90:421–429, 2011

Bantignies F, Cavalli G: Cellular memory and dynamic regulation of polycomb group proteins. Curr Opin Cell Biol 18:275, 2006

Francis NJ, Follmer NE, Simon MD, Aghia G, Butler JD: Polycomb proteins remain bound to chromatin and DNA during DNA replication in vitro. Cell 137:110–122, 2009

Morgan HD, Sutherland HG, Martin DI, Whitelaw E: Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 23:314–318, 1999

Waterland RA, Travisano M, Talibanagi KG, Rached MT, Mirza S: DNA methylation in the human genome. Proc Natl Acad Sci U S A 108:5290–5295, 2011

Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 129:823–837, 2007

Selvi BR, Mohankrishna DV, Ostwal YB, Kundu TK: Small molecule modulators of histone acetylation and methylation: a disease perspective. Biochim Biophys Acta 810:828–2010, 1799

Shi Y: Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8:829–833, 2007

Shi Y, Whestine JR: Dynamic regulation of histone lysine demethylation by demethylases. Mol Cell 25:1–14, 2007

Hoff GC, Hawkins RD, Ren B: Predictive chromatin signatures in the mammalian genome. Hum Mol Genet 18:R195–R201, 2009

Barksis A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 129:823–837, 2007

Pentingat T, Ramon-Krauel M, Cebria J, Diaz R, Jimenez-Chillaron JC: Hypothesis: the “metabolic memory”, the new challenge of transgenerational inheritance at the agouti locus in the mouse. Nat Genet 70:81–120, 2011

Ceriello A: Hypothesis: the “metabolic memory”, the new challenge of transgenerational inheritance at the agouti locus in the mouse. Nat Genet 33:182–187, 2000

Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, Afzal V, Ren B, Rubin EM, Pennacchio LA: ChiP-seq accurately predicts tissue-specific activity of enhancers. Nature 457:854–858, 2009

Yang XJ, Seto E: HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:5310–5318, 2007

Dovey OM, Foster CT, Cowley SM: Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci U S A 107:8242–8247, 2010

Margariti A, Zampetaki A, Xiao Q, Zhou B, Karamariti E, Martin D, Yin X, Mayr M, Li H, Zhang Z, De Falco E, Hu Y, Cockrell G, Xu Q, Zeng L: Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin. Circ Res 106: 1202–1211, 2007

Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber PJ, Epstein JA: HdaC2 regulates the cardiac hypercontractile response by modulating Gsk3β beta activity. Nat Med 13: 324–331, 2007

Shi Y, Hesheitine JR: Dynamic regulation of histone lysine demethylation by demethylases. Mol Cell 25:1–14, 2007

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic kidney disease. Kidney Res Clin Pract 31 (2012) 139–150
de Boer IH, Sun W, Cleary PA, Lachin JM, Moltitch ME, Steffes MW, Zinnman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 365:2366–2376, 2011

[69] White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM: Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol* 126:1707–1715, 2008

[70] de Boer IH, Rue TC, Cleary PA, Lachin JM, Moltitch ME, Steffes MW, Sun W, Zinnman B, Brunzell JD, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM: Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Arch Intern Med* 171:412–420, 2011

Colaguri S, Cull CA, Holman RR: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. prospective diabetes study 61 *Diabetes Care* 25:1410–1417, 2002

[72] Holman RR, Paul SK, Bethel MA, Matthews DE, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359:1577–1589, 2008

[73] Patel A, Macmahon S, Chalmers J, Neil B, Billot L, Woodward M, Marre M, Cooper M, Glassiou P, Grobbée D, Hamet P, Harrrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompont S, de Galan BE, Joshi R, Travers F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358:2560–2572, 2008

[74] Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L, Natarajan R: El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, Siraj ES, Fawcett KA, Barroso I: The genetics of obesity: FTO leads the way. *Trends Genet* 26:266–274, 2010

[75] Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, Wollheim CB, Nitert MD, Ling C: Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA1c levels in human pancreatic islets. *Diabetologia* 54:360–367, 2011

[76] Zhao J, Goldberg J, Brenner JD, Vaccarino V: Global DNA methylation is associated with insulin resistance: a monozygotic twin study. *Diabetes* 61:542–546, 2012

[77] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC, Mirmira RG: DNA methylation profiling identifies epigenetic signatures of primary vascular cells. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. *Genome Res* 21:1601–1615, 2011

[78] Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, Siraj ES, Madaio M: DNA methylation profiling identifies epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. *Diabetes* 60:1304–1313, 2011

[79] Yan SF, Ramasamy R, Bucciacelli LG, Wendt T, Lee JK, Hudson BI, Stern DM, Lalca E, Yan DU, Rong S, Naka LK, Schmidt Y: AM: RAGE and its ligands: a lasting memory in diabetic complications? *Diab Vasc Dis Res* 1:10–20, 2004

[80] Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. *Nat Clin Pract Endocrinol Metab* 4:285–293, 2008

[81] Dolinoy DC, Jirtle RL: Environmental epigenomics in human health and disease. *Environ Mol Mutagen* 49:4–8, 2008

[82] Ling C, Del Guerra S, Lupi R, Rönn T, Granhäll C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S: Epigenetic regulation of PPARC1A in human type 2 diabetic islets and effect on insulin secretion. *Diabetologia* 51:615–622, 2008

[83] Barres R, Ooler ME, Yan J, Rene A, Fritz T, Caidahl K, Krook A, Zierath JR: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. *Cell Metab* 10:189–198, 2009

[84] Nikoskovsh A, Sunkari V, Savu O, Forsberg E, Catrina SB, Brismar K: Epigenetic DNA methylation in the promoters of the Igf1 receptor and insulin genes in db/db mice. *Epigenetics* 6:405–409, 2011

[85] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC, Mirmira RG: DNA methylation profiling identifies epigenetic signatures of primary vascular cells. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. *Genome Res* 21:1601–1615, 2011

[86] Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, Siraj ES, Madaio M: DNA methylation profiling identifies epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. *Diabetes* 60:1304–1313, 2011

[87] Yan SF, Ramasamy R, Bucciacelli LG, Wendt T, Lee JK, Hudson BI, Stern DM, Lalca E, Yan DU, Rong S, Naka LK, Schmidt Y: AM: RAGE and its ligands: a lasting memory in diabetic complications? *Diab Vasc Dis Res* 1:10–20, 2004

[88] Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. *Nat Clin Pract Endocrinol Metab* 4:285–293, 2008

[89] Dolinoy DC, Jirtle RL: Environmental epigenomics in human health and disease. *Environ Mol Mutagen* 49:4–8, 2008

[90] Ling C, Del Guerra S, Lupi R, Rönn T, Granhäll C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S: Epigenetic regulation of PPARC1A in human type 2 diabetic islets and effect on insulin secretion. *Diabetologia* 51:615–622, 2008

[91] Barres R, Ooler ME, Yan J, Rene A, Fritz T, Caidahl K, Krook A, Zierath JR: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. *Cell Metab* 10:189–198, 2009

[92] Nikoskovsh A, Sunkari V, Savu O, Forsberg E, Catrina SB, Brismar K: Epigenetic DNA methylation in the promoters of the Igf1 receptor and insulin genes in db/db mice. *Epigenetics* 6:405–409, 2011

[93] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC, Mirmira RG: DNA methylation profiling identifies epigenetic signatures of primary vascular cells. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. *Genome Res* 21:1601–1615, 2011

[94] Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, Siraj ES, Madaio M: DNA methylation profiling identifies epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. *Diabetes* 60:1304–1313, 2011

[95] Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. *Nat Clin Pract Endocrinol Metab* 4:285–293, 2008

[96] Dolinoy DC, Jirtle RL: Environmental epigenomics in human health and disease. *Environ Mol Mutagen* 49:4–8, 2008

[97] Ling C, Del Guerra S, Lupi R, Rönn T, Granhäll C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S: Epigenetic regulation of PPARC1A in human type 2 diabetic islets and effect on insulin secretion. *Diabetologia* 51:615–622, 2008

[98] Barres R, Ooler ME, Yan J, Rene A, Fritz T, Caidahl K, Krook A, Zierath JR: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. *Cell Metab* 10:189–198, 2009

[99] Nikoskovsh A, Sunkari V, Savu O, Forsberg E, Catrina SB, Brismar K: Epigenetic DNA methylation in the promoters of the Igf1 receptor and insulin genes in db/db mice. *Epigenetics* 6:405–409, 2011

[100] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC, Mirmira RG: DNA methylation profiling identifies epigenetic signatures of primary vascular cells. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. *Genome Res* 21:1601–1615, 2011

[101] Francis J, Babu DA, Deering TG, Chakrabarti SK, Garmey JC, Evans-Molina C, Taylor DG, Mirmira RG: Role of chromatin accessibility in the occupancy and transcription of the insulin gene by the pancreatic and duodenal homeobox factor 1. *Mol Endocrinol* 20:3133–3145, 2006
[138] Cowley Jr AW, Nadeau JH, Baccarelli A, Berecek K, Fornage M, Gibbons GH, Harrison DG, Liang M, Nathanielsz PW, O’Connor DT, Or dovas J, Peng W, Soares MB, Szyl M, Tolunay HE, Wood KC, Zhao K, Galis ZS: Report of the national heart, lung, and blood institute working group on epigenetics and hypertension. Hypertension 59:899–905, 2012

[139] Schones DE, Zhao K: Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 9:179–191, 2008

[140] Maunakea AK, Chepelev I, Zhao K: Epigenome mapping in normal and disease States. Circ Res 107:327–339, 2010

[141] Metzker ML: Sequencing technologies—the next generation. Nat Rev Genet 11:31–46, 2010

[142] Mohn F, Weber M, Schübeler D, Roloff TC: Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol 507:55–64, 2009

[143] Rauch TA, Pfeifer GP: DNA methylation profiling using the methylated-CpG island recovery assay (MIRA). Methods 52:213–217, 2010

[144] Laird PW: Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11:191–203, 2010

[145] Hawkins RD, Hon GC, Ren B: Next-generation genomics: an integrative approach. Nat Rev Genet 11:476–486, 2010

[146] Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW: Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J 30:266–277, 2009

[147] Natarajan R: Drugs targeting epigenetic histone acetylation in vascular smooth muscle cells for restenosis and atherosclerosis. Arterioscler Thromb Vasc Biol 31:725–727, 2011

[148] Yun JM, Jialal I, Devaraj S: Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 22:450–458, 2011. [146]

[149] Chiu J, Khan ZA, Farhangkhoei H, Chakrabarti S: Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 25:964–972, 2009